Annovis Bio Inc. (ANVS): Price and Financial Metrics
GET POWR RATINGS... FREE!
ANVS Stock Price Chart Interactive Chart >
ANVS Price/Volume Stats
| Current price | $18.80 | 52-week high | $23.91 |
| Prev. close | $18.47 | 52-week low | $8.39 |
| Day low | $18.35 | Volume | 66,400 |
| Day high | $19.30 | Avg. volume | 55,649 |
| 50-day MA | $16.31 | Dividend yield | N/A |
| 200-day MA | $13.57 | Market Cap | 153.48M |
Annovis Bio Inc. (ANVS) Company Bio
Annovis Bio, Inc. develops drugs for Alzheimer's and Parkinson's diseases and other neurodegenerative disorders. It offers posiphen compound for mild cognitive impairment and early stage Alzheimer's disease and bisnorcymserine compound that inhibits amyloid formation and prevents the progression of the Alzheimer's disease. The company was founded by Maria Luisa Maccecchini in May 2008 and is headquartered in Berwyn, PA.
Latest ANVS News From Around the Web
Below are the latest news stories about ANNOVIS BIO INC that investors may wish to consider to help them evaluate ANVS as an investment opportunity.
ANNOVIS BIO ANNOUNCES TWO PRESENTATIONS AT THE AD/PD™ 2023 INTERNATIONAL CONFERENCE ON ALZHEIMER'S AND PARKINSON'S DISEASESAnnovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing neurodegenerative diseases, today announced the Company will be making two presentations at the upcoming AD/PD™ 2023 International Conference on Alzheimer's and Parkinson's Disease, which is taking place from March 28 through April 1, 2023, in Gothenburg, Sweden. |
COYA, Dr. Reddy's Sign Deal for Proposed Abatacept BiosimilarCOYA and Dr. Reddy's enter into a license agreement where the latter will source proposed biosimilar of abatacept biosimilar to Coya to develop and commercialize COYA 302. |
Deciphera (DCPH) Gets Breakthrough Tag for Qinlock Expanded UseThe FDA grants breakthrough tag to Qinlock for treating second-line GIST patients with mutations in KIT Exon 11 and 17/18. Stock up on Tuesday in response. |
Mirum's (MIRM) Livmarli Gets FDA Nod for Expanded Use, Stock UpMirum Pharmaceuticals (MIRM) announces FDA approval of Livmarli for infants 3 months and older. Stock up 6% in response to the news. |
Seagen (SGEN) Set to be Acquired by Pfizer for $43 B, Stock UpSeagen is set to be acquired by the large-cap pharma company, Pfizer, at a valuation of $43 billion. The stock is up about 15% in response to the news. |
ANVS Price Returns
| 1-mo | 20.05% |
| 3-mo | N/A |
| 6-mo | 45.17% |
| 1-year | 34.29% |
| 3-year | 417.91% |
| 5-year | N/A |
| YTD | 39.99% |
| 2022 | -23.61% |
| 2021 | 133.16% |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...